Ann: Results of LCT Parkinsons trial require further analysis, page-99

Very disappointed to say the least, more disappointed in the wording and presentation of the release compared to the results (as has been previously said). The results are not bad - they are just not great. But end of the day it still works just not as effectively as was hoped. My opinion is that 26 weeks is not long enough, and to even have a glimmer of resurrecting the share price we need to know the current status of cohort #1 at least as they have surpassed 52 weeks, considering now the unblinding has occurred they should be able to seek that information easily.
PR = rubbish
Results = ok. sub -8 on NTCELL80 is lower than 26 weeks for Phase IIa on UPDRS Part III also. 80 is also 6 points lower than placebo.
Immupel in itself is still impressive, being able to enter the body without requiring the lowering of the immune system, and there's been no product or procedure adverse events during the trial which is nothing but positive.
i am still holding, and will await the strategy meeting and agm outcomes.
cheers